NASDAQ:RVNC - Revance Therapeutics Stock Price, Forecast & News

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Revance Therapeutics Inc (NASDAQ:RVNC) posted its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.96). The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.40 million. View Revance Therapeutics' Earnings History.

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Revance Therapeutics.

Revance Therapeutics will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 equities research analysts have issued 1-year price objectives for Revance Therapeutics' shares. Their forecasts range from $20.00 to $39.00. On average, they expect Revance Therapeutics' stock price to reach $27.33 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

Media stories about RVNC stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Revance Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Revance Therapeutics.

Revance Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 6,590,000 shares, an increase of 9.8% from the December 31st total of 6,000,000 shares. Based on an average daily trading volume, of 661,200 shares, the days-to-cover ratio is currently 10.0 days. Approximately 16.9% of the company's stock are sold short. View Revance Therapeutics' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Myovant Sciences (MYOV), Bristol-Myers Squibb (BMY), Merck & Co., Inc. (MRK), Fate Therapeutics (FATE) and Global Blood Therapeutics (GBT).

Revance Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (10.73%), Franklin Resources Inc. (7.94%), Rice Hall James & Associates LLC (2.36%), State Street Corp (2.34%), Perceptive Advisors LLC (1.82%) and Renaissance Technologies LLC (1.50%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

RVNC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, Rice Hall James & Associates LLC, Citigroup Inc. and Bank of America Corp DE. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.

RVNC stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Alyeska Investment Group L.P., EAM Global Investors LLC, Sei Investments Co., Knights of Columbus Asset Advisors LLC, EAM Investors LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Revance Therapeutics.

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RVNC stock can currently be purchased for approximately $25.33.